Rigel Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)

12 Months Ended

Dec. 31, 2024

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

Schedule of cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments consisted of the following (in thousands):


		As of December 31,
		2024			2023
Cash		$	20,135		$	8,247
Money market funds			16,386			9,685
US treasury bills			7,263			12,594
Government-sponsored enterprise securities			23,177			11,233
Corporate bonds and commercial paper			10,360			15,174
		$	77,321		$	56,933
Reported as:
Cash and cash equivalents		$	56,746		$	32,786
Short-term investments			20,575			24,147
		$	77,321		$	56,933

Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses


					Gross			Gross
		Amortized			Unrealized			Unrealized
As of December 31, 2024		Cost			Gains			Losses			Fair Value
US treasury bills		$	7,260		$	3		$	—		$	7,263
Government-sponsored enterprise securities			23,174			3			—			23,177
Corporate bonds and commercial paper			10,356			4			—			10,360
Total		$	40,790		$	10		$	—		$	40,800


					Gross			Gross
		Amortized			Unrealized			Unrealized
As of December 31, 2023		Cost			Gains			Losses			Fair Value
US treasury bills		$	12,591		$	3		$	—		$	12,594
Government-sponsored enterprise securities			11,230			7			(4)			11,233
Corporate bonds and commercial paper			15,172			5			(3)			15,174
Total		$	38,993		$	15		$	(7)		$	39,001